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Abstract
Objectives: The aim of the analysis was to assess the
accuracy of various FDG-PET/CT parameters in staging
lymph nodes after neoadjuvant chemotherapy.
Methods: In this prospective study, 74 patients with
adenocarcinoma of the esophageal–gastric junction were
examined by FDG-PET/CT in the course of their
neoadjuvant chemotherapy given before surgical treat-
ment. Data from the final FDG-PET/CT examinations
were compared with the histology from the surgical
specimens (gold standard). The accuracy was calculated
for four FDG-PET/CT parameters: (1) hypermetabolic
nodes, (2) large nodes, (3) large-and-medium large nodes,
and (4) hypermetabolic or large nodes.
Results: In 74 patients, a total of 1540 lymph nodes were
obtainedby surgery, and theseweregrouped into287 regions
according to topographic origin. Five hundred and two
nodeswere imagedbyFDG-PET/CTandwere grouped into
these same regions for comparison. In the analysis, (1)
hypermetabolic nodes, (2) large nodes, (3) large-and-
medium large nodes, and (4) hypermetabolic or large nodes
identifiedmetastases inparticular regionswith sensitivitiesof
11.6%, 2.9%, 21.7%, and 13.0%, respectively; specificity was
98.6%, 94.5%, 74.8%, and 93.6%, respectively. The best
accuracy of 77.7% reached the parameter of hypermetabolic
nodes.Accuracydecreased to62.0%whenalso smallernodes
(medium-large) were taken for the parameter of metastases.
Conclusions: FDG-PET/CT proved low sensitivity
and high specificity. Low sensitivity was based on low
detection rate (32.6%) when compared nodes imaged by
FDG-PET/CT to nodes found by surgery, and in inability
to detect micrometastases. Sensitivity increased when also






R0 Radical resection of the cancer
FDG 18F-fluoro-deoxy-glucose
SCC Squamous cell carcinoma
(of the esophagus)
AC Adenocarcinoma (of the esophagus)
PERCIST 1.0 PET response criteria in solid
tumors, version 1.0
EUS Endoscopic ultrasonography
There is little doubt that the malignant involvement of
lymph nodes is a key factor in the outcome of patients
with esophageal carcinoma following radical (R0)
resection [1–4]. However, some disagreement remains as
to the optimal method for nodal staging in esophageal
cancer according to the AJCC scheme [5–7]. Endoscopic
ultrasonography (EUS) is currently considered a more
sensitive tool than computed tomography [7–9] or
contrast-enhanced CT [5] for imaging lymph nodes.
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Metabolic information from integrated FDG-PET/CT
may improve the sensitivity of anatomic evaluation by
CT [10, 11], and some authors have reported good results
in imaging lymph node metastases using FDG [12–14],
but others have not been able to show that such data are
helpful [9, 15]. A number of studies have also been per-
formed in patients with squamous cell carcinoma of the
esophagus [16] (SCC) or with ‘‘esophageal cancer’’ [17].
These patients have various ratios of SCC and adeno-
carcinoma (AC) of the esophagus, and as these types of
carcinoma differ substantially [2, 18, 19], the results of
these studies are only partially applicable to patients with
AC. Confronting our FDG-PET/CT data with histologic
specimens, we concluded FDG-PET/CT to be of low
sensitivity and of high specificity and that is why we tried




One hundred and ﬁfty-three patients with adenocarci-
noma of the esophageal–gastric junction were prospec-
tively recruited to the study between January 2009 and
February 2013 to ascertain the metabolic response to
neoadjuvant chemotherapy. Initial FDG-PET/CT staging
was followed by FDG-PET/CT restaging after the ﬁrst
course of therapy and no earlier than 14 days after the
third course of neoadjuvant chemotherapy. The data from
postchemotherapy examinationswere used in the analysis.
Seventy-four patients (6 female, 68 male; median age
60 years; range 27–74 years) were surgically resected and
were selected for this analysis. The participants were all of
middle European origin; of similar socioeconomic back-
ground; and without deﬁcits in education, living standard,
access to health care, or medical information.
Therapy
Patients received three preoperative and three postoper-
ative cycles of chemotherapy, with surgery performed 3–
6 weeks after completing the third cycle. Intravenous
chemotherapy consisted of epirubicin (50 mg/m2) and
cisplatin (60 mg/m2) with hydration and standard an-
tiemetic prophylaxis on day 1 plus continuous infusion of
fluorouracil (200 mg/m2 daily) for 21 days (ECF) using a
portable infusion pump or oral capecitabine (1.000 mg/
m2 twice daily) for 14 days (ECCap) in a 21 days cycle
(according to the MAGIC regimen) [20, 21]. Depending
on the localization and extent of the tumor, all patients
underwent either transthoracic esophagectomy with
gastric pull-up reconstruction and intrathoracic esopha-
gogastric anastomosis (Ivor–Lewis procedure), or prox-
imally extended total or proximal gastrectomy with
transhiatal resection of the distal esophagus and
suprahiatal anastomosis. All patients that underwent
resection had negative proximal resection margins as
determined by intraoperative frozen histopathological
analysis. Abdominal D1 plus lymphadenectomy (all
lymph node tissue around the left gastric artery, common
hepatic artery, celiac trunk, and proximal half of the
lienal artery) was a standard part of all operations;
radical infracarinal mediastinal lymphadenectomy was
added to transthoracic esophagectomy.
Lymph node imaging
Patients fasted for at least 6 h before intravenous
administration of FDG. Blood glucose levels were
determined in each patient before FDG administration.
The dose of FDG was corrected for patient weight as
recommended by the European Association of Nuclear
Medicine [22]. Examinations were performed without the
application of iodinated contrast material intravenously.
Patients were positioned in a supine head-first position
on the table of a Biograph 40 TruePointTrueV HD PET/
CT scanner (Siemens, Erlangen, Germany). For CT data
acquisition, the following parameters were used: 120 kV,
63 mAs (effective), collimation 24 9 1.2 mm, and slice
thickness 5 mm. Axial images were reconstructed in
2 mm increments using both B19S and B50F kernels. In
all examinations, 3 min/bed position, Gaussian filtra-
tion, kernel 5 mm, matrix size 168 9 168 were used for
PET data acquisition. Using the Siemens TrueX (PSF)
reconstruction algorithm, PET data were reconstructed
in corrected and noncorrected images, with 2 mm
reconstruction increments, three iterations, and 21 sub-
sets. The PERCIST 1.0 protocol was used to maintain
reproducibility as described previously [23, 24].
Surgical sampling of lymph nodes
In 52 out of 74 patients (70.3%) the carcinoma was
classiﬁed as Siewert type I, in 17 out of 74 patients
(23.0%) as Siewert type II, and in 5 out of 74 patients
(6.7%) as Siewert type III [25]. Altogether, 1540 lymph
nodes were surgically resected and subjected to histo-
logical analysis. According to the origin of the speci-
mens, denoted by operating surgeons, topographical
regions were identified. Following the principles of
lymph node classification [26], lymph nodes were as-
sorted into these five regions: region 1, subcarinal nodes;
region 2, periesophageal and preaortal nodes of the lower
mediastinum; region 3, left and right pericardial nodes;
region 4, perigastric nodes along the lesser curvature and
nodes around the left gastric artery; region 5, perivas-
cular nodes. In total, 287 regions (mean 3.8 regions per
patient) comprised the matrix used in the analyses [27].
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Lymph nodes in every region were counted and histo-
logically categorized as metastatic or nonmetastatic.
Lymph node diagnosis by FDG-PET/CT
In the design of the prospective study according to the
PERCIST 1.0 protocol [23], no more than two of the
metastatic lymph nodes were analyzed in each patient.
To enable comparison between nodes imaged after the
chemotherapy and those surgically removed, examina-
tions were re-evaluated from digitally archived data. The
short axis of identified nodes was measured, and FDG
consumption was compared with the background. In this
way, all nodes were categorized according to the diam-
eter of the short axis either large (>1 cm), small
(<0.5 cm), or medium-large (0.5–1 cm), or, according to
their metabolic activity, hypermetabolic (FDG con-
sumption that exceeded the consumption in surrounding
tissue) [28] or nonhypermetabolic. Next, the nodes were
sorted into a matrix identical to that of the surgical
specimens. All evaluations were performed by a single
radiologist with more than 8 years experience in PET/CT
and 20 years in CT diagnostic imaging.
Comparison between the nodes identiﬁed by
FDG-PET/CT and the ones surgically resected
Histological evaluation (gold standard) was considered
positive when at least one metastatic lymph node was
found in a region. FDG-PET/CT evaluation was con-
sidered positive when at least one lymph node bore
pertinent parameters in the analyzed region. Four FDG-
PET/CT parameters were compared to the gold stan-
dard: (1) hypermetabolic nodes, (2) large nodes, (3) large-
and-medium large nodes, and (4) hypermetabolic or
large nodes. Any small and nonhypermetabolic lymph
node was considered negative. For statistical analyses,
regions where lymph nodes were not imaged by FDG-
PET/CT were also classiﬁed as negative.
Results
Accuracy in the detection of lymph nodes
metastases
Only 502 of 1540 surgically resected lymph nodes
(32.6%) were also imaged by FDG-PET/CT (Table 1).
Comparative data for the four FDG-PET/CT parame-
ters and the gold standard have been tabulated (Table 2).
Three of the tested parameters gave similar accuracy:
hypermetabolic nodes (77.7%), hypermetabolic/or large
nodes (74.8%), and large nodes (72.5%). Despite the fact
that the parameter large-and-medium large nodes gave
the best sensitivity (21.7%), it proved the worst specificity
(74.8%) and accuracy (62.0%), which therefore made it
the least reliable for detection of metastases. The other
three parameters produced very few false positives with
the specificity range from 93.6% to 98.6%.
In the analysis, hypermetabolism proved better for
detecting metastatic regions than node size. The single
metabolic parameter, hypermetabolic nodes, proved
positive predictive value of 72.7%, whereas the single
anatomic parameter, large nodes, proved positive pre-
dictive value of 14.3%. Neither combination of parame-
ters ‘‘medium-and-large LNs’’ nor ‘‘hypermetabolic or
large nodes’’ reached the level of metabolic single
parameter when showed positive predictive value of
21.4% and of 39.1%, respectively.
False-negative and false-positive ﬁndings
False negatives were primarily due to the inability of
FDG-PET/CT to image all lymph nodes found at sur-
gery. Less frequent was the situation when nodes were
imaged but not recognized as metastatic due to low
metabolic activity or diameter shorter than 1.0 cm [9].
Only once, large lymph nodes adjacent to the tumor mass
were differentiated from the tumor itself in region 4.
Four out of 218 nonmetastatic regions (1.8%) were
falsely identiﬁed as metastatic ones. In three of them,
different types of inﬂammation were found: a granulo-
matous inﬂammation with anthracosis in region 1, ne-
crotic LNs with foamy histiocytes along with
microscopic ulceration of the tumor in region 4, and
histiocytosis in region 5. No histologic explanation could
be found for one region [29].
Discussion
The exclusive selection of patients does not allow a
general conclusion for all esophageal cancers to be
drawn; on the other hand, our data were not subject to
variability due to biologically different cancers in dif-
ferent localizations.
We were confronted with a low number of lymph
nodes differentiated in CT scans. Although this obser-
vation is not new in the literature [8, 18], the count of
identified nodes was below our expectation. FDG-PET/
CT examinations were carried out at high quality, care-
fully checked for high degree of standardization [24]
according to PERCIST 1.0 protocol and fulfilled current
EANM recommendations [22]. We did not find a way to
improve FDG-PET/CT scans technically by changing
the parameter settings.
The use of more than one radiologist would increase
the reliability of the analysis from the statistical point of
view. With a respect to the anticipated low sensitivity and
high speciﬁcity, we dismissed it as a redundant intent.
Even if a substantially better reader had made the dou-
ble-reading, the increased sensitivity would have been
from clinical point of view still unacceptably low and
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speciﬁcity would have remained still excellent. On the
other hand, when a substantially worse reader had made
the same, speciﬁcity would have dropped slightly, but it
would have been probably still very good, and sensitivity
would have remained unacceptably low.
A cogent reason for the use of high-resolution imag-
ing (i.e., endoscopic ultrasonography) in nodal staging is
the fact that more small lymph nodes can be imaged in
the vicinity of the probe. Such a method could improve
the ratio of imaged/removed lymph nodes and increase
sensitivity [30, 31]. That is why we tested whether in-
creased sensitivity based on imaging of smaller objects
would be also able to improve accuracy in the search for
metastases. We set the threshold for the presence of
metastases down when medium-large nodes 0.5–1.0 cm
were also taken for positive. Using the threshold sensi-
tivity increased 7.5 times compared to the single ana-
tomic parameter. But, an increase of sensitivity was
accompanied by a decrease in specificity of 20% and
accuracy of 15%.
The next weak point in the diagnostics was the inability
of FDG uptake imaging to prove metastases in imaged,
but nonhypermetabolic nodes [28]. In our study, the
parameter of hypermetabolism proved higher accuracy
than node size. Unfortunately, the metabolic information
was not sensitive enough in these diagnostics, but on the
other hand was trustworthy due to the small number of
false-positive findings. PETquantification using SUV is of
special importance when measuring the effect of the
treatment. We have used the PERCIST 1.0 in a longitu-
dinal follow-up of lesions in the prospective study. In this
paper, we have concentrated on a single-time point after
chemotherapy and before surgery. In a single-time point
scenario, utilization of SUV is of a limited value, when
assessing relatively small lymph nodes, where the partial
volume effect artificially lowers the response of the scan-
ner. In this situation, a subjective assessment is more
appropriate in deciding whether the uptake has increased
above that of the adjacent soft tissue. Thereforewe decided
for this type of assessment.
Table 1. Differences in lymph nodes surgically resected and imaged by FDG-PET/CT, divided by regions
Region 1 Region 2 Region 3 Region4 Region 5 Total
N. resected 293 270 215 334 428 1540
N. imaged 146 91 90 90 85 502
(%) 49.8 33.7 41.9 26.9 19.9 32.6
N. resected: lymph nodes (LNs) surgically resected, N. imgaged: LNs imaged by FDG-PET/CT, Region 1: subcarinal LNs, Region 2: periesophageal
LNs of lower mediastinum, Region 3: paracardial LNs, Region 4: perigastric LN, Region 5: perivascular LNs
Table 2. Sensitivity, specificity, and accuracy of all four tested parameters
GS+ GS- Total Estimated value CI95%
(1) Hypermetabolic LNs
Sensitivity 11.6 5.49–22.1
Test+ 8 4 12 Specificity 98.6 95.7–99.6
Test- 61 214 275 Accuracy 77.7 72.3–82.3




Test+ 2 12 14 Specificity 94.5 90.35–97.0
Test- 67 206 273 Accuracy 72.5 66.8–77.5




Test+ 15 55 70 Specificity 74.8 68.4–80.3
Test- 54 163 217 Accuracy 62.0 56.1–67.6




Test+ 9 14 23 Specificity 93.6 89.2–96.3
Test- 60 204 264 Accuracy 74.2 68.7–79.1
Total 69 218 287 PPV 39.1 20.5–61.2
NPV 77.3 71.6–82.1
GS gold standard: GS+ regions with metastatic lymph nodes (LNs) found by histology; GS- regions without metastatic LNs; test+ region where at
least one LN bears tested parameter; test- negative test; SE sensitivity, PPV positive predictive value, NPV negative predictive value; CI 95%:
confidence interval valid for 95% of data
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FDG-PET/CT is a hybrid diagnostic tool where me-
tabolic information provided by PET enhances the ana-
tomic one provided by CT and vice versa. Without
hybrid imaging, the reader would not be able to localize
small hypermetabolic spots to the lymph node [14, 32]
and differentiate small LNs as metastatic ones (Fig. 1).
The simultaneous (‘‘hybrid’’) reading of both modalities
is a robust tool in a nodal staging in routine practice,
despite its low sensitivity.
As a result of our examinations, surgeons looked
pointedly for lymph nodes with excessive metabolism,
where metastases were present at 98.6%. Unfortunately it
only occurred in 11.6% of regions. In other regions,
surgeons sampled nodes blindly according to the stan-
dard protocol.
The low detection rate of removed and imaged LNs
suggested the imaging with higher resolution should be
used for lymph nodes identiﬁcation. But the only ana-
tomic improvement of imaging methods will probably be
devalued by an increase of false positivity. The data
analyzed in the study indicated that to reach higher
accuracy, a higher resolution in lymph nodes imaging
should be accompanied by an improvement of other
nonanatomic parameters whether metabolic (new
radiopharmaceuticals), molecular (MR spectroscopy,
DWI), or others. The identiﬁcation of smaller lymph
nodes alone does not improve the accuracy.
Conclusion
In a homogenous group of 74 patients with adenocarci-
noma of the esophageal–gastric junction, nodal staging
by FDG-PET/CT was not accurate due to the inability of
FDG-PET/CT to image all lymph nodes and to verify
micrometastases or metastases in small lymph nodes.
The parameter ‘‘hypermetabolic nodes’’ proved to be of
low sensitivity, but high speciﬁcity due to the low number
of false-positive ﬁndings. Inﬂammation in lymph nodes
mimicking metastases played a marginal role in this
group of patients. The parameters ‘‘large nodes’’, ‘‘large-
and-medium large nodes’’, and ‘‘large or hypermetabolic
nodes’’ did not improve accuracy for low sensitivity, low
speciﬁcity, or both. Due to low sensitivity, negative
FDG-PET/CT ﬁndings could not exclude the presence of
metastases; high speciﬁcity indicates that any positive
nodal staging must be carefully considered.
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